Abstract |
Small cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in multiple tumor types due to microRNA coregulation. We hypothesize that ROR1-targeted therapy is effective in small cell lung cancer and synergizes with therapeutic BCL2 inhibition. Tissue microarrays (TMAs) and formalin-fixed paraffin-embedded (FFPE) SCLC patient samples were utilized to determine the prevalence of ROR1 and BCL2 expression in SCLC. Eight SCLC-derived cell lines were used to determine the antitumor activity of a small molecule ROR1 inhibitor (KAN0441571C) alone and in combination with the BCL2 inhibitor venetoclax. The Chou-Talalay method was utilized to determine synergy with the drug combination. ROR1 and BCL2 protein expression was identified in 93% (52/56) and 86% (48/56) of SCLC patient samples, respectively. Similarly, ROR1 and BCL2 were shown by qRT-PCR to have elevated expression in 79% (22/28) and 100% (28/28) of SCLC patient samples, respectively. KAN0441571C displayed efficacy in 8 SCLC cell lines, with an IC50 of 500 nM or less. Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.
|
Authors | Walter Z Wang, Konstantin Shilo, Joseph M Amann, Alyssa Shulman, Mohammad Hojjat-Farsangi, Håkan Mellstedt, Johan Schultz, Carlo M Croce, David P Carbone |
Journal | Cell death & disease
(Cell Death Dis)
Vol. 12
Issue 6
Pg. 577
(06 04 2021)
ISSN: 2041-4889 [Electronic] England |
PMID | 34088900
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- BCL2 protein, human
- Bridged Bicyclo Compounds, Heterocyclic
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins c-bcl-2
- Sulfonamides
- ROR1 protein, human
- Receptor Tyrosine Kinase-like Orphan Receptors
- venetoclax
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Bridged Bicyclo Compounds, Heterocyclic
(administration & dosage, pharmacology)
- Cell Line, Tumor
- Drug Synergism
- Humans
- Lung Neoplasms
(drug therapy, genetics, metabolism)
- Molecular Targeted Therapy
- Protein Kinase Inhibitors
(administration & dosage, pharmacology)
- Proto-Oncogene Proteins c-bcl-2
(antagonists & inhibitors, biosynthesis, genetics)
- Receptor Tyrosine Kinase-like Orphan Receptors
(antagonists & inhibitors, biosynthesis, genetics)
- Small Cell Lung Carcinoma
(drug therapy, genetics, metabolism)
- Sulfonamides
(administration & dosage, pharmacology)
- Survival Analysis
|